Attenuated S. typhimurium delivery of STAT3-siRNA and endostatin co-expression plasmids for immune and angiogenesis modulation in colorectal cancer
Year: 2025
Type: article
Abstract: Colorectal cancer (CRC) is the third most common cancer in men and the second most common in women worldwide. Due to its high metastasis rate and poor prognosis, CRC is the leading cause of cancer-related deaths worldwide. Combined gene therapy is a promising treatment that can be used to alter the genes involved in cancer genesis and development. This report describes the use of a eukaryotic co-expression plasmid that encodes both STAT3 siRNAs (si-STAT3) and endostatin for the treatment of CRC homografts in C57BL/6 mice, with attenuated Salmonella typhimurium ( S. typhimurium ) used to facilitate efficient delivery of the plasmid. In this study, single treatment with either si-STAT3 or endostatin showed antitumor effects in the CRC homograft model, and the co-expression treatment had more significant antitumor effects. Not only did the co-expressed plasmids alter the STAT3 and endostatin expression, this treatment also down-regulated MMP2 and cyclin D1 expression and up-regulated caspase 3 expression. The levels of CD4 + T cells, CD8 + T cells, NK cells, and CD4 + CD25 + Foxp3 + regulatory T cells (Treg cells) were also affected by the combined treatment. In addition, the combined therapy altered cytokine expression, enhancing antitumor immunity. The combined gene therapy used in this study additively inhibited colorectal homograft tumor growth. • We employed plasmids that co-expresses endostatin and siRNAs against Stat3, which were delivered by attenuated S. typhimurium , to treat colorectal cancer xenografts. • Besides inducing apoptosis and cell cycle arrest, co-expression plasmids also resulted in regulation of the immunocyte proportion. • Endo-Si-Stat3 co-expression plasmids delivered by attenuated S. typhimurium may represent a novel therapeutic strategy for treatment of human CRC.
Source: Immunobiology
Authors: Ai Cui, Wenyan Fan, Tengyi Huang, Xinyi Li, Wenjing Xiong, Yongni Wang, Yu Chen
Language: English
Subfield: Biotechnology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,840
Award: G4458918634
OpenAlex ID: W7093365854
